Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors

References

• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014;64(24):e139-228
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371(23):2155-66
   PubMed Web of Science ®Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57(11):1251-63
   PubMed Web of Science ®Google Scholar
• Ellis KJ. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009;10(11):1799-817. Available from: http://search.proquest.com.libproxy.lib.unc.edu/docview/228358415?accountid=14244
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98(2):100-8
   PubMed Web of Science ®Google Scholar
• Mao L, Jian C, Changzhi L, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis 2013;106(10):517-27
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010;376(9749):1312-19
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics 2010;20(7):463-5
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009;373(9660):309-17
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu N, Li W, et al. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology 2013;91(3-4):165-72
   PubMed Web of Science ®Google Scholar
• Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost 2013;11(9):1640-6
   PubMed Web of Science ®Google Scholar
• Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012;10(2):199-206
   PubMed Web of Science ®Google Scholar
• Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet 2013;3:318
   PubMedGoogle Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv 2013;82(4):E266-355
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharm Ther 2013;94(3):317-23
   PubMed Web of Science ®Google Scholar
• Lewis JP, Ryan K, O’Connell JR, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 2013;6(2):184-92
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17(1):110-16
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: The GIFT (genotype information and functional testing) study. J Am Coll Cardiol 2012;59(22):1928-37
   PubMed Web of Science ®Google Scholar
• Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011;90(4):568-74
   PubMed Web of Science ®Google Scholar
• Reny JL, Combescure C, Daali Y, et al. PON1 Meta-Analysis Group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis. J Thromb Haemost 2012;10(7):1242-51
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49(24):2312-17
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29(8):992-1000
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 2005;46(10):1827-32
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261-73
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-62
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305(11):1097-105
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363(20):1909-17
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306(20):2221-8
   PubMed Web of Science ®Google Scholar
• Jeong YH, Abadilla KA, Tantry US, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: The results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost 2013;11(6):1194-7
   PubMed Web of Science ®Google Scholar
• Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103(10):1339-43
   PubMed Web of Science ®Google Scholar
• Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur Heart J 2012;33(10):1241-9
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16(4):169-74
   PubMedGoogle Scholar
• Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104(11):1511-15
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52(19):1557-63
   PubMed Web of Science ®Google Scholar
• Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol 2014;10(2):175-89
   PubMed Web of Science ®Google Scholar
• Verheugt FW. Drug interactions with good old clopidogrel: Case closed. JACC Cardiovasc Interv 2013;6(12):1282-3
   Google Scholar
• Ojeifo O, Wiviott SD, Antman EM, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2013;6(12):1275-81
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51(14):1404-11
   PubMed Web of Science ®Google Scholar
• Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010;56(20):1630-6
   PubMed Web of Science ®Google Scholar
• Collet J, Hulot J, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: The randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2). JACC Cardiovasc Interv 2011;4(4):392-402
   PubMed Web of Science ®Google Scholar
• Horenstein RB, Madabushi R, Zineh I, et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol 2014;54(8):865-73
   PubMed Web of Science ®Google Scholar
• Rossi JS, Cammarata M, Dharmavaram J, et al. Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: A pilot study. Pharmacogenomics 2014;15(7):915-23
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367(22):2100-9
   PubMed Web of Science ®Google Scholar
• Lemesle G, Landel JB, Bauters A, et al. Poor agreement between light transmission aggregometry, verify now P2Y(1)(2) and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. Platelets 2014;25(7):499-505
   PubMed Web of Science ®Google Scholar
• Ma W, Liang Y, Zhu J, et al. Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity. Am J Cardiol 2015;115(5):592-601
   PubMed Web of Science ®Google Scholar
• Aradi D, Tornyos A, Pinter T, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: Impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014;63(11):1061-70
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012;59(24):2159-64
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Applying platelet function testing in clinical practice: What are the unmet needs? JAMA 2011;306(11):1260-1
   Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012;125(10):1276-87
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 2010;376(9748):1233-43
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Ruff CT, Mesa RA, et al. Variability of individual platelet reactivity over time in patients treated with clopidogrel: Insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol 2014;64(4):361-8
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013;167(5):2018-23
   PubMed Web of Science ®Google Scholar
• Mayer K, Schulz S, Bernlochner I, et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. results of the ISAR-HPR registry. Thromb Haemost 2014;112(2):342-51
   PubMed Web of Science ®Google Scholar
• Dridi NP, Johansson PI, Clemmensen P, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response–the TAILOR (thrombocytes and IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 2014;25(7):506-12
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Perperis A, Koniari I, et al. Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis 2015
   Google Scholar
• Lee JA, Lee CR, Reed BN, et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 2015;16:303-13
   PubMed Web of Science ®Google Scholar